<DOC>
	<DOCNO>NCT01538966</DOCNO>
	<brief_summary>In study investigator evaluate whether combination low dose somatostatin receptor ligand ( SRL ) weekly daily Pegvisomant attain equivalent control serum IGF-1 level , compare combination high dose SRL weekly Pegvisomant . Lower dose therapy greatly reduce cost acromegaly therapy .</brief_summary>
	<brief_title>Acromegaly Combination Treatment Study</brief_title>
	<detailed_description>The study begin combination Sandostatin LAR Somatuline pegvisomant first administer . Study visit occur every 4 week start study . However , subject make every study visit due distance , study team facilitate monthly blood draw local Quest laboratory facility . After 24 week combination therapy , subject control IGF-1 start Pegvisomant monotherapy dose attain normalization combination therapy . IGF-1 level , liver function test , blood glucose perform monthly . An MRI perform conclusion 48 week treatment period .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Newly diagnose patient acromegaly surgery medical therapy Acromegaly patient least 3 month post surgery , are/are receive adjuvant medical therapy Acromegaly patient SRL monotherapy normal elevate IGF1 level Acromegaly patient Pegvisomant monotherapy normal elevate IGF1 level . Acromegaly patient receive SRL dopamine agonist therapy , 6 week washout period dopamine agonist . Acromegaly patient combination therapy maximum dos SRL Pegvisomant ( daily weekly Normal liver function test randomization treatment The patient appropriate dynamic test pituitary axis , applicable , receive appropriate hormone replacement therapy . The patient harbor macroadenoma visual field defect due chiasmatic compression The patient clinically significant hepatic abnormality and/or aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) 3 time upper limit normal baseline visit . The patient pituitary surgery within 3 month prior study entry The patient radiotherapy within 12 month prior study entry The patient abnormal CBC chemistry panel baseline visit , medical condition ( ) laboratory finding , opinion investigator , might jeopardize patient 's safety . The patient know hypersensitivity test material related compound . The patient history , know current problem alcohol drug abuse . The patient mental condition render patient unable understand nature , scope , possible consequence study , and/or evidence uncooperative attitude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>acromegaly</keyword>
	<keyword>pituitary</keyword>
	<keyword>pegvisomant</keyword>
	<keyword>somavert</keyword>
	<keyword>lanreotide</keyword>
	<keyword>octreotide</keyword>
</DOC>